PE20090771A1 - Derivados de cinolina - Google Patents

Derivados de cinolina

Info

Publication number
PE20090771A1
PE20090771A1 PE2008001053A PE2008001053A PE20090771A1 PE 20090771 A1 PE20090771 A1 PE 20090771A1 PE 2008001053 A PE2008001053 A PE 2008001053A PE 2008001053 A PE2008001053 A PE 2008001053A PE 20090771 A1 PE20090771 A1 PE 20090771A1
Authority
PE
Peru
Prior art keywords
aryl
amino
cinoline
compounds
cinolin
Prior art date
Application number
PE2008001053A
Other languages
English (en)
Inventor
Jeffrey Louis Arriza
Marc Chaelaine
Edward Christian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39811856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090771A1 publication Critical patent/PE20090771A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CINOLINA DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO, ARILO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), ARILO, HETEROARILO, ENTRE OTROS; R3, R4 Y R5 SON CADA UNO H, HALO, CN, NO2, ALQUENILO(C2-C6), ENTRE OTROS; R6 ES ARILO, CICLOALQUILO, HETEROARILO O HETEROCICLOALQUILO OPCIONALMENTE SUSTITUIDOS CON A1, EN DONDE A1 ES HALO, CN, NO2, ALCOXI(C1-C4), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-AMINO-7-FLUORO-8-FENIL-N-PROPIL-CINOLIN-3-CARBOXAMIDA, 4-AMINO-7-CLORO-8-FENIL-N-PROPIL-CINOLIN-3-CARBOXAMIDA, 4-AMINO-7-METOXI-8-FENIL-N-PROPIL-CINOLIN-3-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES GABAA SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA
PE2008001053A 2007-06-19 2008-06-19 Derivados de cinolina PE20090771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94488307P 2007-06-19 2007-06-19

Publications (1)

Publication Number Publication Date
PE20090771A1 true PE20090771A1 (es) 2009-07-23

Family

ID=39811856

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001053A PE20090771A1 (es) 2007-06-19 2008-06-19 Derivados de cinolina

Country Status (15)

Country Link
US (2) US20080318925A1 (es)
EP (1) EP2167091A1 (es)
JP (1) JP2010530406A (es)
KR (1) KR20100039340A (es)
AR (1) AR067028A1 (es)
AU (1) AU2008264985A1 (es)
BR (1) BRPI0813253A2 (es)
CA (1) CA2691648A1 (es)
CL (1) CL2008001837A1 (es)
EC (1) ECSP109885A (es)
IL (1) IL202496A0 (es)
PE (1) PE20090771A1 (es)
TW (1) TW200911760A (es)
UY (1) UY31161A1 (es)
WO (1) WO2008155573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391472T3 (es) * 2005-12-20 2012-11-27 Astrazeneca Ab Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
WO2010123441A1 (en) * 2009-04-21 2010-10-28 Astrazeneca Ab Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders
WO2011021979A1 (en) * 2009-08-18 2011-02-24 Astrazeneca Ab Cinnoline compounds, their preparation, and their use
CN105541759A (zh) * 2016-01-07 2016-05-04 美吉斯制药（厦门）有限公司 一种制备沃替西汀的新方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230713A (en) * 1979-01-19 1980-10-28 Ici Americas Inc. Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds
GB8310266D0 (en) * 1982-05-12 1983-05-18 Ici America Inc Pyrazolopyridine compounds
US4552883A (en) * 1982-06-15 1985-11-12 Ici Americas Inc. Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use
US4563525A (en) * 1983-05-31 1986-01-07 Ici Americas Inc. Process for preparing pyrazolopyridine compounds
GB8329531D0 (en) * 1983-11-04 1983-12-07 Ici America Inc Pyrazolopyridine cycloalkanones
GB8421116D0 (en) * 1984-08-20 1984-09-26 Ici America Inc Alkynyl derivatives
GB8425104D0 (en) * 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
GB8513639D0 (en) * 1985-05-30 1985-07-03 Ici America Inc Cinnoline compounds
GB8610980D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
DD249011A5 (de) * 1986-06-20 1987-08-26 Ici Americas Inc,Us Verfahren zur herstellung von cinnolin-verbindungen
GB8702288D0 (en) * 1987-02-02 1987-03-11 Erba Farmitalia Cinnoline-carboxamides
US4925844A (en) * 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
DE68902490T2 (de) * 1988-02-09 1992-12-24 Ici America Inc Pharmazeutische zusammensetzung.
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
DE19620023C2 (de) * 1996-05-17 2001-03-08 Celanese Chem Europe Gmbh Verfahren zur Herstellung von Phosphinat- oder Phosphonatgruppen enthaltenden tertiären Phosphanen und neue Phosphinatgruppen enthaltende tertiäre Phosphane
DE59607957D1 (de) * 1995-07-25 2001-11-22 Clariant Gmbh Katalysatoren zur durchführung von kreuzkupplungsreaktionen
PT1064243E (pt) * 1998-03-18 2003-03-31 Ciba Sc Holding Ag Reaccoes de acoplamento com catalisadores de paladio
US6362216B1 (en) * 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
DE19916222A1 (de) * 1999-04-10 2000-10-19 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von Biarylen
FR2801584B1 (fr) * 1999-11-26 2003-05-30 Rhodia Chimie Sa Procede de preparation d'un compose polyaromatique
US6984756B2 (en) * 2000-05-19 2006-01-10 Eli Lilly And Company Process for preparing biphenyl compounds
RU2279428C2 (ru) * 2000-09-18 2006-07-10 Эйсай Ко., Лтд. Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7199119B2 (en) * 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US20040167165A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
GB0521563D0 (en) * 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
ES2391472T3 (es) * 2005-12-20 2012-11-27 Astrazeneca Ab Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof

Also Published As

Publication number Publication date
KR20100039340A (ko) 2010-04-15
CL2008001837A1 (es) 2009-06-26
BRPI0813253A2 (pt) 2014-12-30
WO2008155573A1 (en) 2008-12-24
AU2008264985A1 (en) 2008-12-24
TW200911760A (en) 2009-03-16
UY31161A1 (es) 2009-01-30
JP2010530406A (ja) 2010-09-09
IL202496A0 (en) 2010-06-30
AR067028A1 (es) 2009-09-30
US20080318925A1 (en) 2008-12-25
ECSP109885A (es) 2010-02-26
CA2691648A1 (en) 2008-12-24
EP2167091A1 (en) 2010-03-31
US20100184738A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
CY1119101T1 (el) Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων
PE20130647A1 (es) Indoles
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
ES2590504T3 (es) N-ciclilamidas como nematicidas
PE20130155A1 (es) Derivados de ariletinilo
AR074648A1 (es) Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20120666A1 (es) Inhibidores de los virus flaviviridae
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20121358A1 (es) Derivados de indol como inhibidores itk
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20142164A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
NI201000011A (es) Derivados de pirimidina 934.
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
ECSP10010058A (es) Derivados de quinazolinadiona, su preparación y sus aplicaciones terapéuticas
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer

Legal Events

Date Code Title Description
FD Application declared void or lapsed